SAN DIEGO, Feb. 09, 2018 -- A new story published by The Recover talks controversy regarding the FDA’s decision to classify the herbal supplement Kratom as an opioid. After months of public comments and a computer-generated model study showing the herb has potential for abuse, the potential ruling has sparked an uproar in the research community. Saying that the computer-generated report was not thorough enough and made generalizations that can harm the potential positive uses for the drug.
|
|||||
Kratom is a natural herb that is derived from South Asia, similar to heroin’s origins. The leaf extracts are used both as a stimulant and as a sedative, depending on the dose. The active ingredients are the alkaloids mitragynine and 7-hydroxymitragynine, which have shown evidence of pain relieving and anti-inflammatory effects. It’s commonly used to treat fibromyalgia and diabetes. Its leaves are dried and fortified into powders and then made into pill form, or brewed like a tea. The different strands are used for different ailments and have different purposes when ingested. Treatments range from Diabetes blood sugar management, use as an Immune system booster, and most commonly as an opioid withdrawal aid.
Researchers from both North Carolina and Florida say the FDA did not compile acceptable research to be able to classify the drug the same schedule as heroin, LSD or Ecstasy. "They make a lot of hay of using a computer model, but it's really nice to validate the findings with actual science… Just because it binds, it doesn't mean it has the same efficacy (as an opioid)” Says Scott Hemby of the Department of Basic Pharmaceutical Sciences at High Point University in North Carolina.
Researchers agree the alkaloids contained in Kratom to bind to receptors the way opioids do, but at a milder level. The plant as whole has a much smaller potential for abuse than the alkaloids themselves.
The Recover lists treatment centers around the country along with information about substance abuse and mental health. Read the original story here https://www.therecover.com/researchers-fighting-fdas-decision-kratom/
Author: Kevin Leonard
Organization: TheRecover.com
Address: 27420 Jefferson Ave, Temecula, CA 92590
Phone: 888-510-3898
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/36e5c7d7-8b3e-4493-bbcf-75a24855fced


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 



